The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's oral pill for psoriasis, the company said.

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas home phototherapy offered lower costs for patients and payers, according to a ...

By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, ...

The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.